• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

海洋源生物活性化合物:一种有潜力的免疫疗法治疗手段。

Bioactive compounds derived from marine source: a potential immunotherapy treatment.

机构信息

Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan.

Faculty of Science and Natural Resources, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia.

出版信息

J Biomol Struct Dyn. 2024 Jul;42(11):5657-5668. doi: 10.1080/07391102.2023.2227717. Epub 2023 Jun 30.

DOI:10.1080/07391102.2023.2227717
PMID:37387587
Abstract

Immunotherapy using checkpoint inhibitors blocks the checkpoint proteins (programmed cell death receptor-1; PD-1) from binding with their corresponding ligands (programmed cell death receptor ligand-1; PD-L1) to regulate cell signaling pathways. The marine environment holds a huge source of small molecules that are understudied which can be developed as an inhibitor. Hence, this study investigated the inhibitory effect of 19 algae-derived small molecules against PD-L1 by using molecular docking, absorption, distribution, metabolism, and elimination (ADME) properties and molecular dynamics simulations (MDS). The molecular docking revealed that the binding energy of the six best compounds ranges from -11.1 to -9.1 kcal/mol. Fucoxanthinol, in particular, has the strongest binding energy at -11.1 kcal/mol with three hydrogen bonds (ASN:63A, GLN:66A, and ASP:122A). Meanwhile, the MDS demonstrated that the ligands were strongly bound to the protein, indicating the stability of the complexes. In summary, the identified compounds are potential PD-L1 inhibitors in immunotherapy.Communicated by Ramaswamy H. Sarma.

摘要

免疫疗法使用检查点抑制剂阻止检查点蛋白(程序性死亡受体-1;PD-1)与其相应的配体(程序性死亡受体配体-1;PD-L1)结合,从而调节细胞信号通路。海洋环境蕴藏着大量未被充分研究的小分子,这些小分子可以被开发成抑制剂。因此,本研究通过分子对接、吸收、分布、代谢和消除(ADME)特性以及分子动力学模拟(MDS),研究了 19 种藻类来源的小分子对 PD-L1 的抑制作用。分子对接结果表明,六种最佳化合物的结合能范围在-11.1 到-9.1 kcal/mol 之间。特别是岩藻黄质醇具有最强的结合能,为-11.1 kcal/mol,与三个氢键(ASN:63A、GLN:66A 和 ASP:122A)结合。同时,MDS 表明配体与蛋白质结合牢固,表明复合物的稳定性。综上所述,鉴定出的化合物是免疫疗法中潜在的 PD-L1 抑制剂。Ramaswamy H. Sarma 通讯。

相似文献

1
Bioactive compounds derived from marine source: a potential immunotherapy treatment.海洋源生物活性化合物:一种有潜力的免疫疗法治疗手段。
J Biomol Struct Dyn. 2024 Jul;42(11):5657-5668. doi: 10.1080/07391102.2023.2227717. Epub 2023 Jun 30.
2
Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein.基于结构的小分子抑制剂搜索与分子动力学驱动能量相结合,用于研究人类程序性细胞死亡蛋白 1(PD-1)。
J Biomol Struct Dyn. 2023;41(24):14771-14785. doi: 10.1080/07391102.2023.2188958. Epub 2023 Mar 16.
3
Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint.含异恶唑联苯衍生物作为靶向程序性细胞死亡蛋白1/程序性细胞死亡配体1免疫检查点的小分子抑制剂的设计、合成及生物学评价
Mol Divers. 2022 Feb;26(1):245-264. doi: 10.1007/s11030-021-10208-4. Epub 2021 Mar 30.
4
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.发现低分子量抗 PD-L1 肽用于癌症免疫治疗。
J Immunother Cancer. 2019 Oct 22;7(1):270. doi: 10.1186/s40425-019-0705-y.
5
Computational discovery of small drug-like compounds as potential inhibitors of PD-1/PD-L1 interactions.计算发现小分子药物样化合物作为 PD-1/PD-L1 相互作用潜在抑制剂。
J Biomol Struct Dyn. 2023 Jul;41(11):5345-5361. doi: 10.1080/07391102.2022.2085805. Epub 2022 Jun 13.
6
Molecular Mechanism of Food-Derived Polyphenols on PD-L1 Dimerization: A Molecular Dynamics Simulation Study.食物来源的多酚对 PD-L1 二聚化的分子机制:分子动力学模拟研究。
Int J Mol Sci. 2021 Oct 10;22(20):10924. doi: 10.3390/ijms222010924.
7
Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through "ring fusion" strategy.通过“环融合”策略发现苯并[d]异噻唑衍生物作为靶向程序性细胞死亡蛋白1/程序性细胞死亡配体1(PD-1/PD-L1)相互作用的新型支架抑制剂。
Bioorg Chem. 2022 Jun;123:105769. doi: 10.1016/j.bioorg.2022.105769. Epub 2022 Apr 4.
8
In silico exploration of PD-L1 binding compounds: Structure-based virtual screening, molecular docking, and MD simulation.基于结构的虚拟筛选、分子对接和 MD 模拟:PD-L1 结合化合物的计算探索。
PLoS One. 2024 Aug 9;19(8):e0306804. doi: 10.1371/journal.pone.0306804. eCollection 2024.
9
Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors.PD-1/PD-L1 复合物抑制剂结合模式的分子建模研究。
Int J Mol Sci. 2019 Sep 19;20(18):4654. doi: 10.3390/ijms20184654.
10
Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab.免疫检查点程序性死亡蛋白 1,PD-1 的分子动力学:配体 PD-L1 和单克隆抗体 nivolumab 结合时 BC 环构象的变化。
BMC Bioinformatics. 2020 Dec 14;21(Suppl 17):557. doi: 10.1186/s12859-020-03904-9.

引用本文的文献

1
Anticancer Properties of Macroalgae: A Comprehensive Review.大型海藻的抗癌特性:全面综述
Mar Drugs. 2025 Feb 7;23(2):70. doi: 10.3390/md23020070.